Hilde S. Ørbo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Hilde S. Ørbo has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Joseph Sexton
Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
3 shared publicationsJørgen Jahnsen
Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
3 shared publicationsAnne T. Tveter
Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
2 shared publications- Asia-Sophia Wolf
Division of Infection Control, Section for Immunology, Norwegian Institute of Public Health, Oslo, Norway
2 shared publications - Daniel H. Solomon
Division of Rheumatology, Brigham and Women’s Hospital, Boston, USA
2 shared publications Espen A. Haavardsholm
Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway
2 shared publications
Latest Publications
- 25 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 724-733
Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time‐Series Analyses
Objective: Hyperuricemia (HU) and gout are common in postmenopausal women. We aimed to identify the longitudinal changes in serum urate (SU) levels during and after the menopausal transition and its interaction with coexisting SU‐modifying conditions. Methods: This longitudinal study included Japanese women who underwent annual medical examinations from April 2004 to September 2024 and had at least one visit before and after self‐reported menopause. Menopausal transition stages were categorized into premenopause, perimenopause (5 years before and up to the menopause), and postmenopause. Longitudinal changes in SU and HU (SU ≥6.8 mg/dL or taking medications for gout or HU) were examined by interrupted time‐series analyses and evaluated across stratified subgroups. Results: We analyzed 8,169 eligible participants with 93,511 visits over a median follow‐up of 13.8 years. SU levels gradually increased during premenopause, rose sharply over perimenopause, and stabilized in postmenopause. Compared to premenopause, the mean SU level was 0.41 mg/dL (95% confidence interval: 0.38–0.43) higher in postmenopause. HU prevalence increased from 2 ) and a high body mass index (≥25) with HU were greater in postmenopause; HU was observed in approximately 18% of overweight or obese women at menopause. Conclusion: SU levels rapidly increase during perimenopause and are already elevated by the time of menopause. Maintaining a normal body weight and preserving kidney function before menopause may decrease postmenopausal HU and potentially prevent subsequent gout in women. image
- 25 January 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (3) , 724-733
Longitudinal Changes in Serum Urate Levels From Premenopause Through Postmenopause: Interrupted Time‐Series Analyses
Objective: Hyperuricemia (HU) and gout are common in postmenopausal women. We aimed to identify the longitudinal changes in serum urate (SU) levels during and after the menopausal transition and its interaction with coexisting SU‐modifying conditions. Methods: This longitudinal study included Japanese women who underwent annual medical examinations from April 2004 to September 2024 and had at least one visit before and after self‐reported menopause. Menopausal transition stages were categorized into premenopause, perimenopause (5 years before and up to the menopause), and postmenopause. Longitudinal changes in SU and HU (SU ≥6.8 mg/dL or taking medications for gout or HU) were examined by interrupted time‐series analyses and evaluated across stratified subgroups. Results: We analyzed 8,169 eligible participants with 93,511 visits over a median follow‐up of 13.8 years. SU levels gradually increased during premenopause, rose sharply over perimenopause, and stabilized in postmenopause. Compared to premenopause, the mean SU level was 0.41 mg/dL (95% confidence interval: 0.38–0.43) higher in postmenopause. HU prevalence increased from 2 ) and a high body mass index (≥25) with HU were greater in postmenopause; HU was observed in approximately 18% of overweight or obese women at menopause. Conclusion: SU levels rapidly increase during perimenopause and are already elevated by the time of menopause. Maintaining a normal body weight and preserving kidney function before menopause may decrease postmenopausal HU and potentially prevent subsequent gout in women. image
- Open Access
- 15 November 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 48, 101121
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
- 15 November 2024
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 48, 101121
Open AccessHumoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
- Open Access
- 10 September 2024
- Published by Elsevier in EBioMedicine
- Vol. 108, 105317
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
- 10 September 2024
- Published by Elsevier in EBioMedicine
- Vol. 108, 105317
Open AccessT cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
- Open Access
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Objectives To assess incidence, severity and predictors of COVID-19, including protective post-vaccination levels of antibodies to the receptor-binding domain of SARS-CoV-2 spike protein (anti-RBD), informing further vaccine strategies for patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive medication. Methods IMIDs on immunosuppressives and healthy controls (HC) receiving SARS-CoV-2 vaccines were included in this prospective observational study. COVID-19 and outcome were registered and anti-RBD antibodies measured 2–5 weeks post-immunisation. Results Between 15 February 2021 and 15 February 2023, 1729 IMIDs and 350 HC provided blood samples and self-reported COVID-19. The incidence of COVID-19 was 66% in patients and 67% in HC, with re-infection occurring in 12% of patients. Severe COVID-19 was recorded in 22 (2%) patients and no HC. No COVID-19-related deaths occurred. Vaccine-induced immunity gave higher risk of COVID-19 (HR 5.89 (95% CI 4.45 to 7.80)) than hybrid immunity. Post-immunisation anti-RBD levels Conclusion Vaccinated patients with IMID have a low risk of severe COVID-19. Hybrid immunity lowers the risk of infection. High post-immunisation anti-RBD levels protect against COVID-19. These results suggest that knowledge on COVID-19 history, and assessment of antibody levels post-immunisation can help individualise vaccination programme series in high-risk individuals. Trial registration number NCT04798625.
Open AccessIncidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
Objectives To assess incidence, severity and predictors of COVID-19, including protective post-vaccination levels of antibodies to the receptor-binding domain of SARS-CoV-2 spike protein (anti-RBD), informing further vaccine strategies for patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive medication. Methods IMIDs on immunosuppressives and healthy controls (HC) receiving SARS-CoV-2 vaccines were included in this prospective observational study. COVID-19 and outcome were registered and anti-RBD antibodies measured 2–5 weeks post-immunisation. Results Between 15 February 2021 and 15 February 2023, 1729 IMIDs and 350 HC provided blood samples and self-reported COVID-19. The incidence of COVID-19 was 66% in patients and 67% in HC, with re-infection occurring in 12% of patients. Severe COVID-19 was recorded in 22 (2%) patients and no HC. No COVID-19-related deaths occurred. Vaccine-induced immunity gave higher risk of COVID-19 (HR 5.89 (95% CI 4.45 to 7.80)) than hybrid immunity. Post-immunisation anti-RBD levels Conclusion Vaccinated patients with IMID have a low risk of severe COVID-19. Hybrid immunity lowers the risk of infection. High post-immunisation anti-RBD levels protect against COVID-19. These results suggest that knowledge on COVID-19 history, and assessment of antibody levels post-immunisation can help individualise vaccination programme series in high-risk individuals. Trial registration number NCT04798625.